{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:51:09Z","timestamp":1781891469765,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007688","name":"American University of Beirut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.retram.2026.103576","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:54:19Z","timestamp":1772672059000},"page":"103576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed\/refractory acute myeloid leukemia: A global perspective"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-9134","authenticated-orcid":false,"given":"Iman","family":"Abou Dalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaher","family":"Chakhachiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Moukalled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"El Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103576_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"22","key":"10.1016\/j.retram.2026.103576_bib0002","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2026.103576_bib0003","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.retram.2026.103576_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.retram.2026.103576_bib0005","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.retram.2026.103576_bib0006","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.retram.2026.103576_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.retram.2026.103576_bib0008","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2026.103576_bib0009","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.retram.2026.103576_bib0010","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2026.103576_bib0011","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.retram.2026.103576_bib0012","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.retram.2026.103576_bib0013","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.retram.2026.103576_bib0014","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"33","key":"10.1016\/j.retram.2026.103576_bib0015","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to Cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2026.103576_bib0016","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.retram.2026.103576_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","article-title":"Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103576_bib0018","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1182\/blood-2023-185524","article-title":"Cladribine and low-dose cytarabine-based salvage therapy for relapsed\/refractory AML in a predominantly venetoclax-exposed cohort","volume":"142","author":"Cheung","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103576_bib0019","first-page":"2706","article-title":"Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent","volume":"109","author":"Steinauer","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.retram.2026.103576_bib0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.retram.2026.103576_bib0021","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103576_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2024-202620","article-title":"Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemia","volume":"144","author":"Bataller","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103576_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35388","article-title":"Lower intensity therapy with cladribine\/low dose cytarabine\/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation","author":"Senapati","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.retram.2026.103576_bib0024","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00277-025-06389-9","article-title":"Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed\/refractory acute myeloid leukemia: results of a single center study","volume":"104","author":"Zhu","year":"2025","journal-title":"Ann Hematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:56:33Z","timestamp":1781888193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2452318626000139"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103576","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed\/refractory acute myeloid leukemia: A global perspective","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103576"}}